phosphocreatine and Carcinoma--Squamous-Cell

We developed a new transvaginal coil tuned for phosphorous-31 and measured its magnetic resonance spectroscopy ((31)P MRS) of uterine cervical cancer. In a 50-year-old woman with uterine cervical cancer (International Federation of Gynecology and Obstetrics [FIGO] stage IIIb), (31)P MRS with the new coil clearly differentiated the low intensity of phosphocreatinine (PCr) and high intensity of phosphomonoester (PME) in tumor from those in muscle. Results suggests that this method will be useful for assessing uterine cervical cancer.

Topics: Carcinoma, Squamous Cell; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Middle Aged; Phosphocreatine; Phosphorus Isotopes; Uterine Cervical Neoplasms

31Phosphorus magnetic resonance spectroscopy (31P-MRS) provides biochemical information in a noninvasive way. The aim of this work was: (a) to characterize the 31P spectrum of advanced head and neck tumors, and (b) to evaluate the spectral changes after treatment and to correlate them with the pathologic response.. A total of 20 patients diagnosed with advanced head and neck tumors and 7 healthy controls participated in the study. The tumor mass and its contralateral side were studied by means of 31P-MRS before and after treatment. Neck muscles of a control group were also studied.. Tumors presented ratios of phosphomonoesters (PME), phosphodiesters (PDE), and inorganic phosphate (Pi) with respect to the adenosine triphosphate (ATP), significantly higher and a PCr (phosphocreatine)/ATP ratio lower than the neck muscle of volunteers or the contralateral side. The PDE/ATP and PME/ATP ratio values obtained before therapy were similar, independent of the later response to treatment. However, when there was a complete response, the ratios measured after treatment were decreased.. These results show the existence of significant differences between the 31phosphorus spectrum of tumors and neck muscle, but also between the tumors and their contralateral sides. Moreover, 31P-MRS is able to detect metabolic changes after a complete response. These results suggest that 31P-MRS would be useful in the evaluation of the clinical response of head and neck tumors.

Topics: Adenosine Triphosphate; Aged; Carcinoma, Squamous Cell; Esters; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neck Muscles; Phosphocreatine; Phosphorus

Under full nutrient in vitro conditions, the cellular adenylate energy charge of six different rodent and human tumor cell types was identical, i.e., 0.94 +/- 0.01, suggesting the potential utility of this parameter as a cell (and tissue) independent marker of nutrient deprivation and hypoxia, across tumor types. The adenylate energy charge values of tumors, arising from these cells, was reduced and variable ranging from 0.72 to 0.91 for the various tumor types. However, neither the tumor adenylate energy charge, NTP/Pi, nor PCr/Pi ratios correlated with the radiobiologic hypoxic cell fractions across tumor types. The reduced adenylate energy charge in vivo suggests varying degrees of nutrient deprivation in the different tumor types, however, factors other than or in addition to hypoxia likely contribute to tumor energy status.

Topics: Adenine Nucleotides; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line; Cell Survival; Energy Metabolism; Female; Glioma; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasms; Neoplasms, Experimental; Pharyngeal Neoplasms; Phosphates; Phosphocreatine; Ribonucleotides; Sarcoma, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured; Whole-Body Irradiation

Studies were performed to characterize phosphorus-31 magnetic resonance (MR) spectra obtained from 10 superficial human tumors outside the brain and to determine whether P-31 MR spectroscopy could allow detection of a response to therapy before a change in tumor size was measured. The ratio of phosphomonoester to adenosine triphosphate peak intensities (PME/ATP) was unusually large in all tumors studied. The average PME/ATP in lymphomas (1.8 +/- 0.5) was greater than in nonlymphoma cancers (1.1 +/- 0.15). The average PME/ATP for all tumors studied (1.4 +/- 0.5) was much greater than that of underlying skeletal muscle (0.23 +/- .09). Eight of the tumors were studied before and after therapy. Responders were distinguished from nonresponders on the basis of changes in tumor size. PME/ATP decreased during therapy in three lymphomas that responded to therapy. In an adenocarcinoma and Ewing sarcoma that did not respond to therapy, PME/ATP increased. PME/ATP remained constant in two squamous cell carcinomas that responded to therapy and decreased in one squamous cell carcinoma that decreased in size by 40% but was classified as a nonresponder. Changes in PME/ATP did not always parallel changes in tumor size during therapy. In two patients, a decrease in PME/ATP preceded a decrease in tumor size. In four patients, PME/ATP increased transiently during periods when tumor size remained constant.

Topics: Adenosine Triphosphate; Axilla; Carcinoma, Squamous Cell; Groin; Head and Neck Neoplasms; Humans; Lymphoma; Magnetic Resonance Spectroscopy; Neoplasms; Phosphocreatine

A 1.4-T magnetic resonance (MR) imager was modified to perform MR spectroscopy measurements. The implementation involved only a few additions in hardware and practically no change in software. Procedures for acquiring the MR spectra are similar to those for MR images. Both sensitivity and homogeneity were found to be adequate over a region 12 cm in diameter. Typical scanning times are 4.5 minutes for human brain, 2.8 minutes for muscle, and 20-35 minutes for solid tumors. Preliminary spectral studies of the metabolism of human brains, tumors, and a muscle of the forearm during exercise obtained with the modified system are presented.

Topics: Adenosine Triphosphate; Adult; Animals; Brain; Carcinoma, Squamous Cell; Humans; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Male; Melanoma; Mice; Muscle Contraction; Muscles; Phosphates; Phosphocreatine; Software; Tissue Extracts